Pfizer Inc. agreed to acquire privately held FoldRx Pharmaceuticals, whose leading drug candidate is a therapy for a genetic neurodegenerative disease for which the only current therapy is a liver transplant.

read more>>

AUSTIN, Texas - Atrial Fibrillation (A Fib) — a type of heart rhythm disorder that affects the electrical system, or "wiring," of the heart muscle — is often referred to as the "silent killer," and can suddenly trigger a massive, debilitating stroke or even death. During September &"Wh

read more>>

The otoprotective effects of AM-111, Auris Medical’s novel intracellular drug for the treatment of inner ear disorders, have been further confirmed by promising new data presented at the Inner Ear Biology Workshop 2010 in Prague (Czech Republic). A research group led by Prof. Kiyofumi Gyo (T

read more>>

NEW YORK -- NewYork-Presbyterian Hospital/Columbia University Medical Center has established a new center devoted to research and treatment of pre-leukemia blood disordersKnown as the Myelodysplastic Syndromes Center, it is one of the largest programs of its kind in the nationMyelodysplastic synd

read more>>

KUALA LUMPUR -- Malaysia is considering releasing genetically modified mosquitoes designed to combat dengue fever, in a landmark field trial that has come in for criticism from environmentalistsIn the first experiment of its kind in Asia, 2,000-3,000 male Aedes aegypti mosquitoes would be released

read more>>

SAN DIEGO -- Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, today announced the commercial launch of its proprietary PROMETHEUS® Crohn's Prognostic testThis novel and unique diagnostic represents a significant advance in the Prometheus Inflammatory Bowel Disea

read more>>

TIRAT CARMEL, Israel -- InSightec Ltd., the global leader in MR guided focused ultrasound technology and the only company to receive FDA approval for its ExAblate(R) system for treating uterine fibroids, announced today that its ExAblate(R) system has been used for the first time for the treatment

read more>>

CAMBRIDGE, Mass. -- Stromedix, Inc., a biotechnology company focused on innovative therapies for fibrosis and fibrotic organ failure, announced today that its lead clinical candidate STX-100 has been granted orphan drug status by the U.S. Food and Drug Administration (FDA) for the treatment of The

read more>>

ROME -- A New Tool is Targeted to Specialists in PKU, Offering an Advanced Educational Pathway Consisting of CME Accredited e-Learning ModulesPKU specialists around the world can now count on a brand-new, authoritative website entirely dedicated to this rare genetic disorder, which affects one out

read more>>

HOUSTON -- As one of the leading medical centers in the U.S. diagnosing and treating twin-to-twin transfusion syndrome (TTTS), Texas Children's Fetal Center is proud to announce the successful completion of its 200th TTTS laser ablation surgeryTo view a video about TTTS and learn about the importa

read more>>